First GLP‑1 pill OK'd
The FDA approved oral semaglutide (Wegovy) as the first GLP‑1 pill for weight loss — a major shift from injectables to an oral option. This approval opens a new chapter in obesity treatment and will likely reshape prescribing, nutrition planning, and demand for weight‑loss therapies. (ajmc.com)
The regulatory decision was issued Dec. 22, 2025, and Novo Nordisk signaled a full U.S. commercial launch in early January 2026 with a 1.5 mg starter dose to be made available at a self‑pay price of $149 per month. (prnewswire.com) In the pivotal OASIS‑4 phase 3 study of 307 adults, the per‑protocol analysis showed a 16.6% mean weight reduction at 64 weeks for people on oral semaglutide 25 mg, while the treatment‑policy (intention‑to‑treat) analysis reported a 13.6% mean reduction. (appliedclinicaltrialsonline.com) OASIS‑4 reported that roughly one in three participants on the 25 mg pill lost 20% or more of body weight at 64 weeks in the efficacy analysis, compared with about 3% in the placebo group. (novonordisk.mediaroom.com) Gastrointestinal events were the most common adverse reactions: nausea occurred in about 46.6% of treated patients versus 18.6% with placebo, and vomiting in about 30.9% versus 5.9% with placebo, while serious adverse events were reported less frequently on active treatment in the trial. (novonordisk.mediaroom.com) The company says the pill will be manufactured in U.S. facilities (North Carolina) with “robust supply on‑hand,” and noted the Wegovy brand has been prescribed to roughly 3.2 million people in the U.S. to date. (prnewswire.com) Novo Nordisk and outlets reporting the launch highlighted telehealth and pharmacy distribution plans and confirmed early availability through select providers and savings offers starting with the initial January rollout. (cnbc.com)
